Lexeo Therapeutics LXEO
Lexeo Therapeutics FY 2024: net loss $98.3M; diluted EPS −$3.09
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-25-043486
- Document
- 10-K
- Exhibit 10.24
- Material contract
- Exhibit 10.27
- Material contract
- Exhibit 10.28
- Material contract
- Exhibit 10.29
- Material contract
- Exhibit 10.30
- Material contract
- Exhibit 10.31
- Material contract
- Exhibit 10.32
- Material contract
Key figures from this report
These are the numbers Lexeo Therapeutics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$98.3MAgainst −$66.4M in FY 202310-K income statement, on EDGAR
- Diluted EPS−$3.09Against −$12.40 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$35.0M−71% from $121.5M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$81.2MAgainst −$59.5M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- SELLAS Life Sciences Group SLS public float $219M, Jun 30, 2025
- Precigen PGEN public float $219M, Jun 30, 2025
- Perspective Therapeutics CATX public float $213M, Jun 30, 2025
- Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025
- Natures Sunshine Products NATR public float $211M, Jun 30, 2025